Useful prognostic tools based on complete blood cell counts in diffuse large B-cell lymphoma

被引:7
作者
Shimono, Joji [1 ,2 ]
Takahashi, Shogo [1 ]
Takemura, Ryo [1 ]
Kakinoki, Yasutaka [1 ]
机构
[1] Asahikawa City Hosp, Dept Hematol, Kinsei Cho 1-1-65, Asahikawa, Hokkaido 0708610, Japan
[2] Hokkaido Univ, Grad Sch Med, Fac Med, Dept Hematol, Sapporo, Hokkaido, Japan
关键词
complete blood cell counts; diffuse large B-cell lymphoma; lymphocyte; absolute monocyte counts ratio; malignant lymphoma; prognostic factor; INDEX NCCN-IPI; LYMPHOCYTE/MONOCYTE RATIO; MONOCYTE RATIO; FOLLICULAR LYMPHOMA; R-IPI; RITUXIMAB; ANEMIA; PREDICTION; IMPACT; SCORE;
D O I
10.1111/ijlh.13106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma. Three prognostic factors are widely used in DLBCL: International Prognostic Index (IPI), Revised-IPI (R-IPI), and National Comprehensive Cancer Network-IPI (NCCN-IPI). Method We established a prognostic model using peripheral blood absolute lymphocyte/absolute monocyte counts ratio (LMR), hemoglobin, and platelet counts obtained from complete blood cell counts (CBC) data at diagnosis based on 214 cases of DLBCL who received more than one course of R-CHOP therapy at a single institution. Results The cutoff values for using the receiver operating characteristics (ROC) curve for LMR, hemoglobin, and platelet counts were 1.6, 100 g/L, and 150 x 10(9)/L, respectively. Stratification was performed using the three factors (LMR < 1.6, hemoglobin < 100 g/L, and platelet counts < 150 x 10(9)/L). CBC Group 1 (none of the 3 factors) included 92 cases, CBC Group 2 (1 or 2 of these factors) included 108 cases, and CBC Group 3 (all 3 factors) included 11 cases. The 5-year OS rates were 78.2%, 60.9%, and 10.1%, respectively. In multivariate analysis, CBC Group 3 (hazard ratio, 2.9760; 95% confidence interval, 1.2670-6.991; P = .01) were prognostic factors for OS. CBC Group 3 had factors based on which the further stratification of the poor prognosis group into IPI high-risk and R-IPI poor-risk groups (P = .01, <.0001, respectively) was possible. Conclusions In DLBCL, combination of three CBC parameters has the potential to be a useful prognostic tool.
引用
收藏
页码:754 / 761
页数:8
相关论文
共 35 条
  • [1] Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma
    Adams, Hugo J. A.
    de Klerk, John M. H.
    Fijnheer, Rob
    Heggelman, Ben G. F.
    Dubois, Stefan V.
    Nievelstein, Rutger A. J.
    Kwee, Thomas C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11) : 671 - 679
  • [2] [Anonymous], 2017, WHO CLASSIFICATION T
  • [3] Peripheral Blood Lymphocyte/Monocyte Ratio Predicts Outcome in Follicular Lymphoma and in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era
    Belotti, Angelo
    Doni, Elisa
    Bolis, Silvia
    Rossini, Fausto
    Casaroli, Ivana
    Pezzatti, Sara
    Pogliani, Enrico Maria
    Pioltelli, Pietro Enrico
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (04) : 208 - 213
  • [4] Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
    Chapuy, Bjoern
    Stewart, Chip
    Dunford, Andrew J.
    Kim, Jaegil
    Kamburov, Atanas
    Redd, Robert A.
    Lawrence, Mike S.
    Roemer, Margaretha G. M.
    Li, Amy J.
    Ziepert, Marita
    Staiger, Annette M.
    Wala, Jeremiah A.
    Ducar, Matthew D.
    Leshchiner, Ignaty
    Rheinbay, Ester
    Taylor-Weiner, Amaro
    Coughlin, Caroline A.
    Hess, Julian M.
    Pedamallu, Chandra S.
    Livitz, Dimitri
    Rosebrock, Daniel
    Rosenberg, Mara
    Tracy, Adam A.
    Horn, Heike
    van Hummelen, Paul
    Feldman, Andrew L.
    Link, Brian K.
    Novak, Anne J.
    Cerhan, James R.
    Habermann, Thomas M.
    Siebert, Reiner
    Rosenwald, Andreas
    Thorner, Aaron R.
    Meyerson, Matthew L.
    Golub, Todd R.
    Beroukhim, Rameen
    Wulf, Gerald G.
    Ott, German
    Rodig, Scott J.
    Monti, Stefano
    Neuberg, Donna S.
    Loeffler, Markus
    Pfreundschuh, Michael
    Truemper, Lorenz
    Getz, Gad
    Shipp, Margaret A.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 679 - +
  • [5] Prognostic Value of Platelet Count in Diffuse Large B-Cell Lymphoma
    Chen, Ling-Ping
    Lin, Shyh-Jer
    Yu, Ming-Sun
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (01) : 32 - 37
  • [6] Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Chen, Yu-Mu
    Lai, Chien-Hao
    Chang, Huang-Chih
    Chao, Tung-Ying
    Tseng, Chia-Cheng
    Fang, Wen-Feng
    Wang, Chin-Chou
    Chung, Yu-Hsiu
    Wang, Yi-Hsi
    Su, Mao-Chang
    Huang, Kuo-Tung
    Chen, Hung-Chen
    Chang, Ya-Chun
    Lin, Meng-Chih
    [J]. PLOS ONE, 2015, 10 (08):
  • [7] Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model
    Deng, Qiwen
    He, Bangshun
    Liu, Xian
    Yue, Jin
    Ying, Houqun
    Pan, Yuqin
    Sun, Huiling
    Chen, Jie
    Wang, Feng
    Gao, Tianyi
    Zhang, Lei
    Wang, Shukui
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [8] Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma
    El-Galaly, Tarec Christoffer
    Villa, Diego
    Alzahrani, Musa
    Hansen, Jakob Werner
    Sehn, Laurie H.
    Wilson, Don
    Brown, Peter de Nully
    Loft, Annika
    Iyer, Victor
    Johnsen, Hans Erik
    Savage, Kerry J.
    Connors, Joseph M.
    Hutchings, Martin
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (11) : 1041 - 1046
  • [9] Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma Useful Prognostic Tools in the Rituximab Era
    Ho, Ching-Liang
    Lu, Chieh-Sheng
    Chen, Jia-Hong
    Chen, Yu-Guang
    Huang, Tzu-Chuan
    Wu, Yi-Ying
    [J]. MEDICINE, 2015, 94 (24)
  • [10] Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
    Hong, Junshik
    Woo, Hyun Seon
    Kim, Hyunchul
    Ahn, Hee Kyung
    Sym, Sun Jin
    Park, Jinny
    Ahn, Jeong Yeal
    Cho, Eun Kyung
    Shin, Dong Bok
    Lee, Jae Hoon
    [J]. CANCER SCIENCE, 2014, 105 (12): : 1569 - 1575